Search

Your search keyword '"Humira (Medication) -- Prices and rates"' showing total 4 results
Start Over Descriptor "Humira (Medication) -- Prices and rates" Topic drugs -- prices and rates
4 results on '"Humira (Medication) -- Prices and rates"'

1. HEARING EXPOSES GREED OF DRUG CORPORATION ABBVIE

Subjects
Drugs -- Prices and rates, Company pricing policy, News, opinion and commentary, Imbruvica (Medication) -- Prices and rates, Humira (Medication) -- Prices and rates
Abstract

WASHINGTON, DC -- The following information was released by the Alliance for Retired Americans: According to a study released on May 18 by the U.S. House Oversight and Reform Committee, [...]

Published
2021

2. COMMITTEE TO HOLD HEARING WITH ABBVIE CEO AND EXPERTS ON PRICING PRACTICES FOR HUMIRA AND IMBRUVICA MAY

Subjects
AbbVie Inc. -- Political activity -- Prices and rates, Chief executive officers -- Political aspects -- Political activity, Drugs -- Prices and rates, Chairpersons -- Political activity -- Political aspects, Pharmaceutical industry -- Prices and rates -- Political aspects -- Political activity, Company pricing policy, News, opinion and commentary, Imbruvica (Medication) -- Prices and rates, Humira (Medication) -- Prices and rates
Abstract

WASHINGTON, DC -- The following information was released by the U.S. House of Representatives Committee on Oversight and Government Reform: On Tuesday, May 18, 2021, at 10:00 a.m., Rep. Carolyn [...]

Published
2021

3. AbbVie's Humira defense may keep prices high, but it's still legal, judge rules

Author

Sagonowsky, Eric

Subjects
Defense industry -- Prices and rates, Drugs -- Prices and rates, Antitrust law, Defense industry, Antitrust issue, Company pricing policy, Pharmaceuticals and cosmetics industries, Humira (Medication) -- Prices and rates
Abstract

Byline: Eric Sagonowsky AbbVie reaps billions of dollars annually from its big-selling immunology medicine Humira, and, under deals with biosimilar makers, the drug is likely free from U.S. competition until [...]

Published
2020

4. New drugs offer hope at huge price

Author

Merx, Katie

Subjects
Biological products industry -- Product development, Pharmaceutical industry -- Product development, Drugs -- Prescribing, Drugs -- Prices and rates, Company pricing policy, Business, Business, regional, General interest, Humira (Medication) -- Prices and rates
Published
2005

Catalog

Books, media, physical & digital resources
See catalog results